Nitrome Biosciences (Nitrome) is a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders.
Nitrome Biosciences is initially targeting Parkinson’s disease and developing cures for multiple aging-dependent diseases, including other neurodegenerative diseases, Type II diabetes, heart disease and cancer.
Nitrome Biosciences was founded in 2017 by Irene Griswold-Prenner. The company is headquartered in San Francisco, California.
Nitrome Biosciences is developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s.
Nitrome Biosciences has raised $38M in a Series A round on April 21, 2020. The investment was co-led by Sofinnova Partners and AbbVie Ventures, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments.